胸腔积液中白细胞介素-17 升高是肺癌患者的诊断标志物和预后预测因子。
Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.
机构信息
First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing 210029, China.
出版信息
Eur J Med Res. 2014 May 8;19(1):23. doi: 10.1186/2047-783X-19-23.
BACKGROUND
Interleukin 17 (IL-17) is a proinflammatory cytokine produced mainly by CD4(+) T-lymphocytes and may be important in tumor cell growth and progression. In this study, we aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of IL-17 in lung cancer patients with malignant pleural effusion (MPE).
METHODS
Pleural effusion samples were collected from 78 lung cancer patients with MPE and from 45 patients with nonmalignant pleural effusion. Pleural fluid concentrations of IL-17 were measured by using enzyme-linked immunosorbent assays.
RESULTS
Malignant effusion exhibited higher IL-17 levels than nonmalignant effusion (20.49 ± 5.27 pg/ml vs. 13.16 ± 2.25 pg/ml; P < 0.01). Lung cancer patients with pleural fluid IL-17 levels below 15 pg/ml had longer overall survival than those patients with higher levels (10.8 months vs. 4.7 months; P < 0.05). On the basis of multivariate analysis, we found that pleural fluid IL-17 level was an independent prognostic factor in lung cancer patients with MPE.
CONCLUSIONS
Measurement of IL-17 levels might be a useful diagnostic and prognostic test for lung cancer patients with MPE.
背景
白细胞介素 17（IL-17）是一种主要由 CD4+T 淋巴细胞产生的促炎细胞因子，可能在肿瘤细胞生长和进展中起重要作用。在这项研究中，我们旨在评估胸腔积液中白细胞介素 17 水平在肺癌合并恶性胸腔积液（MPE）患者中的诊断和预后价值。
方法
收集 78 例肺癌合并 MPE 患者和 45 例非恶性胸腔积液患者的胸腔积液样本。采用酶联免疫吸附试验测定胸腔液中 IL-17 的浓度。
结果
恶性胸腔积液中的 IL-17 水平高于非恶性胸腔积液（20.49±5.27pg/ml 比 13.16±2.25pg/ml；P<0.01）。胸腔积液中 IL-17 水平低于 15pg/ml 的肺癌患者总生存期长于 IL-17 水平较高的患者（10.8 个月比 4.7 个月；P<0.05）。基于多变量分析，我们发现胸腔液中 IL-17 水平是肺癌合并 MPE 患者的独立预后因素。
结论
IL-17 水平的测定可能是肺癌合并 MPE 患者的一种有用的诊断和预后检测方法。
Zotero 插件